Company: AGIO
Filing Date: 2025-10-30
Form Type: 10-Q
Source: 0001439222-25-000116
Chunk: 120

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-10-30
Form: 10-Q
Item: Part I, Item 1
Chunk 120
---
— — — 42 Common stock issued under stock incentive plan and ESPP123,568 — 1,099 — — — — 1,099 Stock-based compensation expense— — 11,565 — — — — 11,565 Net loss— — — — (96,118)— — (96,118)Balance at June 30, 202473,091,490 $73 $2,464,284 $(1,045)$(1,000,316)(16,216,411)$(802,486)$660,510 Unrealized gain on available-for-sale securities— — — 4,465 — — — 4,465 Common stock issued under stock incentive plan and ESPP146,464 — 2,637 — — — — 2,637 Stock-based compensation expense— — 11,145 — — — — 11,145 Net income— — — — 947,915 — — 947,915 Balance at September 30, 202473,237,954 $73 $2,478,066 $3,420 $(52,401)(16,216,411)$(802,486)$1,626,672 

See accompanying Notes to Condensed Consolidated Financial Statements.

5

AGIOS PHARMACEUTICALS, INC.Condensed Consolidated Statements of Cash Flows(Unaudited)Nine Months EndedSeptember 30,(In thousands)20252024Operating activitiesNet (loss) income$(304,742)$770,248 Adjustments to reconcile net (loss) income to net cash used in operating activities:Depreciation and amortization3,911 4,286 Stock-based compensation expense38,428 31,944 Net accretion of discount on marketable securities(5,442)(8,870)Loss (gain) on disposal of property and equipment304 (39)Non-cash operating lease expense9,229 8,568 Expense associated with license agreement10,000 — Realized gain on investments— (168)Gain on sale of contingent payments— (889,136)Milestone payment from gain on sale of oncology business— (200,000)Changes in operating assets and liabilities: